{"sent_idx": "151", "frame_idx": "8", "ev": "Median oxytocin plasma levels at the three time points for SRI treated versus placebo treated patients, respectively, were: baseline 32.1 (22.7, 39.5) vs 31.2 (22.6, 39.5), after 1 week 30.4 (22.5, 40.5) vs 36.1 (25.1, 47.3), after 4 weeks 36.7 (27.3, 43.8) vs 37.0 (26.1, 43.6), and intra-individual range 11.6 (5.1, 16.8) vs 7.4 (5.8, 12.4).", "icos": [["1", "SRI", "placebo", "Median oxytocin plasma levels"]], "sample": "x"}
{"sent_idx": "8", "frame_idx": "0", "ev": "During treatment, plasma oxytocin did not differ between SRI and placebo treatment.", "icos": [["0.97639334", "placebo", "selective serotonin reuptake inhibitors ( SSRI", "plasma oxytocin"], ["0.96765745", "placebo", "SSRI", "plasma oxytocin"], ["0.96501535", "placebo", "SRI", "plasma oxytocin"], ["0.9369571", "placebo", "SRIs ( venlafaxine or SSRI )", "plasma oxytocin"], ["0.930184", "placebo", "Oxytocin", "plasma oxytocin"]], "sample": "c"}
{"sent_idx": "22", "frame_idx": "1", "ev": "During treatment, plasma oxytocin did not differ between SRI and placebo treatment.", "icos": [["0.97639334", "placebo", "selective serotonin reuptake inhibitors ( SSRI", "plasma oxytocin"], ["0.96765745", "placebo", "SSRI", "plasma oxytocin"], ["0.96501535", "placebo", "SRI", "plasma oxytocin"], ["0.9369571", "placebo", "SRIs ( venlafaxine or SSRI )", "plasma oxytocin"], ["0.930184", "placebo", "Oxytocin", "plasma oxytocin"]], "sample": "c"}
{"sent_idx": "62", "frame_idx": "2", "ev": "Clomipramine treatment, ranging between 8.5 and 34 months, caused an overall increase of CSF oxytocin by 11%.", "icos": [["0.9995184", "Clomipramine", "Clomipramine", "CSF oxytocin"], ["0.9995184", "Clomipramine", "clomipramine", "CSF oxytocin"], ["0.6351405", "Clomipramine", "clozapine", "CSF oxytocin"], ["0.2312046", "Clomipramine", "cognitive or behavioral psychotherapy", "CSF oxytocin"], ["0.058578465", "Clomipramine", "heparin", "CSF oxytocin"]], "sample": "c"}
{"sent_idx": "159", "frame_idx": "11", "ev": "The sole placebo responder had an increase of oxytocin within the highest quartile between baseline and week 4.", "icos": [["0.9799145", "placebo", "intranasal oxytocin", "oxytocin"], ["0.972329", "placebo", "Oxytocin", "oxytocin"], ["0.972329", "placebo", "oxytocin", "oxytocin"], ["0.96979094", "placebo", "SSRI", "oxytocin"], ["0.9655127", "placebo", "SRI", "oxytocin"]], "sample": "c"}
{"sent_idx": "177", "frame_idx": "15", "ev": "In comparisons between all SRI treated and all placebo treated patients, no significant differences appeared for any of the oxytocin measures.", "icos": [["0.9974432", "SRI", "placebo", "plasma oxytocin measures"], ["0.99737203", "SRI", "placebo", "baseline oxytocin ."], ["0.9972964", "SRI", "placebo", "Plasma oxytocin medians"], ["0.9972934", "SRI", "placebo", "intra - individual oxytocin range"], ["0.997209", "SRI", "placebo", "Median plasma oxytocin"]], "sample": "o"}
